Aralez Pharmaceuticals Inc

Aralez Pharmaceuticals — Jefferies Healthcare Conference 2016

17 slides from Aralez Pharmaceuticals's conference presentation, Jun 9, 2016

  1. Slide 1: Forward-looking statements

    This presentation includes certain statements that constitute “forward-looking statements” within the meaning of applicable securities laws. Forward-looking statements include, but are not limited to, statements regarding the successful execution of our commercialization strategy with respect to Fib

  2. Slide 2: The Aralez Investment Thesis

    The Aralez Investment Thesis Aralez is an emerging global specialty pharmaceutical company designed to: Maximize the value of a broadened portfolio, growing revenue base and geographic footprint across North America and Europe Build on our anchor positions in cardiovascular disease and pain manageme

  3. Slide 3: Aralez: The Base Business

    Aralez: The Base Business Canadian Revenue Base Key contributors include Cambia®, Durela® & Soriatane® Ongoing Royalty Stream Receive a 10% royalty on U.S. and ex-US sales of VIMOVO®; Patented until 2031 Receive 20% of CPPIB receipts on TREXIMET® starting in April 2018 Evolving Cardiovascular Portfo

  4. Slide 4: FIBRICOR: Commercial Objectives

    FIBRICOR: Commercial Objectives Drive broader utilization among targets and educate HCPs on how to Rx Capitalize on copay program Leverage affordability and flexibility of both the brand and AG 105 mg script is not substitutable Objective: Increase market share from the fenofibrate/fenofibric acid m

  5. Slide 5: FIBRICOR Performance – Early Indicators

    FIBRICOR Performance – Early Indicators Source: Symphony Health Phast Fibricor Franchise Weekly NRx Began Promotion with 25 Reps 50% lift in NRX volume

  6. Slide 6: YOSPRALA Positioning & Regulatory Status

    YOSPRALA Positioning & Regulatory Status YOSPRALA has a coordinated delivery mechanism composed of an enteric-coated aspirin (325 mg or 81mg core), surrounded by immediate-release omeprazole (40 mg) for the secondary prevention of heart attack and stroke for patients at risk for an aspirin-induced u

  7. Slide 7: YOSPRALA: Phase 3 Clinical Data

    PA32540-301 and PA32540-302 ITT Population; PA32540 (n=524), EC ASA (n=525). PA32540-treated subjects had significantly fewer UGI symptoms. Overall occurrence of major adverse cardiovascular events (MACE) was low, with no significant differences between treatments in types or incidence of MACE. P <

  8. Slide 8: Challenges of Compliance with Aspirin Therapy

    Adjusted HR HR, hazard ratio within the first 6 months 2. Derogar M et al. Clin Gastroenterol Hepatol. 2013;11(1):38-42. Odds Ratio 3.1* P=0.0001 * OR=3.14 (1.75–5.61). 1. Biondi-Zoccai GG et al. Eur Heart J. 2006;27(22):2667-2674. Nonadherence to Aspirin Therapy is Associated with a 3-FOLD Higher R

  9. Slide 9: Disease Awareness and Education Initiatives

    Disease Awareness and Education Initiatives There may be a hole in his aspirin therapy New guidelines published in the Journal of The American College of Cardiology provide opportunity for other advocacy groups to refresh their recommendations Aspirin is assumed in EVERY instance of Dual Antiplatele

  10. Slide 10: YOSPRALA: U.S. Market Share Opportunity

    18.3M 70% take aspirin2 6.3M take aspirin plus PPI/H23 26.2M secondary prevention patients1 Mozaffarian D, Heart Disease and Stroke Statistics – 2015 Update. Fang J, Use of Low-dose Aspirin as Secondary Prevention of Atherosclerotic CVD among US adults (From the National Health Interview Survey, 201

  11. Slide 11: YOSPRALA: Commercial Readiness and Strategy

    YOSPRALA: Commercial Readiness and Strategy Deployed a 25 person high quality sales force that has started promotion of Fibricor and is building relationships with key cardiologists Upon FDA approval, plan to launch YOSPRALA with ~110 sales professionals (including 25 previously hired for Fibricor),

  12. Slide 12: Aralez: Global Regulatory Update

    Aralez: Global Regulatory Update U.S.: YOSPRALA (PA32540/PA8140) NDA filing 505b(2) application; NDA recently resubmitted FDA PDUFA goal date of September 14, 2016; targeting launch in 4Q 2016 EUROPE: PA10040 MAA filing (YOSPRALA) US NDA package will form core of submission CMC, bioequivalence and p

  13. Slide 13: Aralez: A Compelling Platform for Growth

    Aralez: A Compelling Platform for Growth Canadian domiciled with an Irish presence Aralez Pharmaceuticals Trading DAC holds IP & plans to execute acquisition and operating strategy Corporate structure offers competitive advantage Strong balance sheet and financial position As of 1Q16, cash of approx

  14. Slide 14: Business Development: Value Creation Strategy

    Aligned, value creating and transformative M&A Primary Focus on the U.S. and Canada and selective global expansion Opportunistic Approach to Other Specialty Therapeutic Areas Business Development: Value Creation Strategy Near-term EBITDA Accretive & Revenue Generating Products Approved Products in C

  15. Slide 15: Aralez - Our Near Term Priorities

    Aralez - Our Near Term Priorities Continue financially disciplined build up of organization Commercial execution of the recent promotional launch of Fibricor YOSPRALA PDUFA goal date of September 14, 2016; target launch in 4Q 2016, pending FDA approval Plan to submit YOSPRALA in Europe in 4Q 2016 an

  16. Slide 16: Corporate Overview & Strategic Vision

    “Corporate Overview & Strategic Vision” Jefferies Healthcare Conference June 9, 2016

  17. Slide 17: Aralez Pharmaceuticals – Jefferies Healthcare Conference

    /rale2 Pharmaceuticals Breathing New Life Into Pharmaceuticals™ Jefferies Healthcare Conference “Corporate Overview & Strategic Vision” June 9, 2016

Aralez Pharmaceuticals — Jefferies Healthcare Conference 2016 on 6ix